Of note, repotrectinib is currently under investigation while lorlatinib has recently been approved for ALK-rearranged NSCLC patients and is the current preferred second-line treatment in case of no evidence of G2032R mutation and/or bypass signalling [114]. Here, ALK is linked to non-small cell lung carcinoma.